<DOC>
	<DOCNO>NCT02164604</DOCNO>
	<brief_summary>Retinopathy prematurity ( ROP ) neovascular retinal disorder premature bear child , characterize development retinal neovascularisation , macular drag eventually retinal detachment . ROP lead cause childhood blindness , especially develop country . Vascular endothelial growth factor ( VEGF ) play important role development disease . Recently , BEAT ROP study test efficacy intravitreal bevacizumab stage 3 plus ROP prospective , control , randomize , stratify , multicenter trial . Authors find bevacizumab show significant benefit Zone I Zone II disease , continuation peripheral retinal vessel growth treatment . The author also conclude safety could assess due small sample size . Other author raise concern regard result BEAT ROP study safety bevacizumab . The investigator suspect good safety profile ranibizumab treat stage 3 plus ROP . Here present outcome 6 eye ROP stage 3 plus treated single injection ranibizumab .</brief_summary>
	<brief_title>Lucentis Treat Retinopathy Prematurity ( ROP ) 3 Plus Disease</brief_title>
	<detailed_description>The outcome six eye ROP stage 3 plus treat one single intravitreal injection ranibizumab present . Safety issue side affect discuss . Follow 6 month .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Retinopathy Prematurity</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>ROP stage 3 plus disease Severe systemic comorbidity allow systemic sedation injection , antiVEGF ( vascual endothelial growth factor ) therapy contraindicate</criteria>
	<gender>All</gender>
	<minimum_age>32 Weeks</minimum_age>
	<maximum_age>40 Weeks</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>ranibizumab</keyword>
	<keyword>intravitreal therapy</keyword>
	<keyword>ROP</keyword>
	<keyword>Plus disease</keyword>
	<keyword>stage 3 plus</keyword>
</DOC>